MedRise Medical News
Curated medical news, policy updates, and residency-relevant headlines for students, residents, and GME programs.
NewsFDA Approves Gazyva, the First Drug for Primary Membranous NephropathyThe FDA approved obinutuzumab (Gazyva) on Nov. 13, 2026, as the first drug for primary membranous nephropathy: 36% complete remission vs 6% on tacrolimus.
NewsAMA Will Push to Scrap USMLE Surcharges of $210 and $235 for IMGs Testing AbroadThe AMA adopted policy on Nov. 10, 2026, to push for ending USMLE surcharges of $210 (Step 1) and $235 (Step 2 CK) for IMGs who test abroad.
NewsFDA Approves Asundexian, the First Factor XIa Inhibitor, for Secondary Stroke PreventionThe FDA approved asundexian (Sunharbo) on Nov. 9, 2026, the first factor XIa inhibitor, for secondary stroke prevention. What trainees should know.
NewsCMS Awards Final 200 Section 126 Residency Slots to 99 Teaching HospitalsCMS posted the fifth and final round of Section 126 Medicare-funded residency slots on Nov. 9, 2026. What 200 new GME positions mean for students and IMGs.
NewsNeuralink Wins U.K. Approval for GB-PRIME Brain-Implant Study After $650 Million RaiseNeuralink received U.K. regulatory and ethics approvals for GB-PRIME, a feasibility study of its N1 brain implant at two NHS hospitals, two months after closing a $650 million funding round.
NewsSpatial AI Takes Center Stage at AI4: The Next Frontier in 3D IntelligencePublished August 13, 2025. This recap covers a session at the Ai4 2025 conference in Las Vegas (August 11–13, 2025) and has not been updated. At the AI4…
NewsFDA Grants Breakthrough Therapy Designation to Dyne's DYNE-251 for DuchenneFDA gave DYNE-251 (z-rostudirsen) Breakthrough Therapy Designation for Duchenne in August 2025. Its FDA decision date is now January 21, 2027.
NewsJoby Buys Blade's Passenger Business as Blade's Organ-Transport Arm Becomes StrataJoby agreed to buy Blade's passenger business for up to $125M; Blade's organ-transport arm, renamed Strata, named Joby its preferred eVTOL partner.
AnalysisFrom a 250% Threat to a 100% Tariff: Where U.S. Tariffs on Imported Drugs StandIn August 2025 the President said tariffs on imported medicines could reach 250%. In April 2026 a Section 232 proclamation set 100% tariffs on patented drugs, with wide exemptions for generics and companies with pricing deals.
NewsHHS Releases MAHA Children's Health Report and Plans Administration for a Healthy AmericaThe MAHA Commission's May 2025 assessment and HHS's plan for an Administration for a Healthy America, fact-checked against HHS sources.
NewsWhite House Presses 17 Drugmakers on Medicaid Prices as HHS Relaunches HealthData.govJuly 2025 letters gave 17 drugmakers until Sept. 29 to commit to most-favored-nation prices, as HHS relaunched HealthData.gov. Fact-checked.
NewsCMS Health Tech Ecosystem: More Than 60 Companies Pledge to Build Interoperable AppsMore than 60 companies pledged to join CMS's Health Tech Ecosystem in July 2025. What they committed to, fact-checked against CMS sources.
NewsGoogle Releases MedGemma, Open AI Models That Draft Chest X-Ray ReportsGoogle's open MedGemma models read X-rays, CT and MRI. What its 81% chest X-ray figure really measured, what changed in 2026, and what blinded tests found.
NewsIvermectin Mass Drug Administration Cuts Malaria Infections 26% in Kenya: BOHEMIA TrialThe NEJM BOHEMIA trial found monthly community-wide ivermectin cut malaria infection in Kenyan children by 26%. What the drug does and doesn't do.Book a free strategy call
Ten minutes to look at your exam date, your scores and what is getting in the way.